Discovery Life Sciences’ Post

A recent clinical trial has shown promising results, with three autoimmune disease patients responding positively to an allogeneic CD19-directed CAR-T therapy. Read more: https://lnkd.in/erWcyBB5 This is the first clinical proof-of-concept demonstrating the efficacy and safety of an “off the shelf” cell therapy for autoimmune disease, marking a significant milestone for the field! Learn how Discovery's expertise in donor recruitment and management can propel advancements in allogeneic cell therapy development for cancers, autoimmune diseases, and more: https://lnkd.in/gHyaMqQA #CARTCellTherapy #AutoimmuneDiseases #Allogeneic

👩⚕️ For the first time ever, 𝗮𝗹𝗹𝗼𝗴𝗲𝗻𝗲𝗶𝗰 𝗖𝗔𝗥-𝗧 cells have been successfully used to treat an 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲! This is an approach traditionally applied in cancer therapy, but now it opens new doors for millions battling autoimmune conditions like lupus and multiple sclerosis. 𝙒𝙝𝙮 𝙞𝙨 𝙩𝙝𝙞𝙨 𝙖 𝙜𝙖𝙢𝙚-𝙘𝙝𝙖𝙣𝙜𝙚𝙧, you ask? 🔬 Until now, CAR-T cell therapy was limited to oncology. This breakthrough marks its debut in autoimmune disease treatment, showcasing the versatility and potential of this cutting-edge technology. 💡 Allogeneic CAR-T cells, derived from healthy donors, provide a more accessible and potentially more effective treatment option compared to patient-specific therapies. 💪 This new method promises targeted treatment, reduced side effects, and improved efficacy, potentially leading to long-term remission and enhanced quality of life for patients. This milestone exemplifies the rapid advancements in genetic engineering and immunotherapy, offering hope and new possibilities for millions. Exciting times ahead in the fight against autoimmune diseases! #Biotechnology #HealthcareInnovation #CAR_TCells #AutoimmuneDisease #MedicalBreakthrough #GeneTherapy #PrecisionMedicine read the full story here: https://lnkd.in/eFE8j_gv

Detecting pancreatic cancer through changes in body composition and metabolism

Endocrine complications occur in 40–60% of survivors of cancer, including hypothalamic–pituitary disorders, dysregulation of steroid and peptide hormones, and dysregulation of bone and metabolism. A Review piece highlights common symptoms related to endocrine disorders & proposes a practical approach to diagnose affected patients: https://hubs.li/Q02SvKVg0 Figure: Common endocrine complications in long-term cancer survivors.

🚀 Exciting Trends in Cell Therapy! 🚀 Thanks for Dr. Liang Cao's input! I foresee two major trends shaping the future of Cell Therapy: 1️⃣ Allogeneic "off-the-shelf" formulations. 2️⃣ The increasing focus on diseases caused by #Bcells, especially those resulting from their malfunction or abnormal activity. These can be broadly categorized into autoimmune diseases, immunodeficiencies, and B cell malignancies, including: 👉 Autoimmune Diseases: - Systemic Lupus Erythematosus (SLE): Autoantibodies from B cells target the body’s own tissues, causing inflammation and damage. - Rheumatoid Arthritis: B cells produce rheumatoid factors against the synovium, leading to chronic joint inflammation. - Type 1 Diabetes: B cells may create antibodies attacking insulin-producing beta cells in the pancreas. - Multiple Sclerosis: B cells form autoreactive antibodies attacking the myelin sheath of nerve cells. - Graves' Disease: Autoantibodies from B cells stimulate the thyroid gland, leading to hyperthyroidism. 👉Immunodeficiencies: - Common Variable Immunodeficiency (CVID): Characterized by low serum immunoglobulins and increased infection susceptibility due to defective B cell differentiation. - X-linked Agammaglobulinemia (XLA): Mutations in the BTK gene result in an absence of mature B cells and severely reduced immunoglobulin levels. 👉B Cell Malignancies: - Chronic Lymphocytic Leukemia (CLL): Uncontrolled B cell growth in the bone marrow and blood. - Non-Hodgkin Lymphoma: Includes cancers like diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma originating in B cells. - Multiple Myeloma: Cancer of plasma cells (a type of B cell) producing abnormal antibodies, damaging bones and other tissues. 👉Other Conditions: - Waldenström's Macroglobulinemia: A rare non-Hodgkin lymphoma where abnormal B cells produce large amounts of IgM antibodies, thickening the blood and causing systemic symptoms. These conditions vary widely in symptoms, severity, and treatment approaches. Stay informed and engaged with the latest advancements in the field! #CellTherapy #CART #Biotech #AutoimmuneDiseases #Immunodeficiencies #BCellMalignancies #HealthcareInnovation #Biocytogen 🔗

CAR T cell therapy continues to revolutionise cancer treatments and researchers in Germany are also exploring its potential to treat autoimmune disorders. Research findings published in the New England Journal of Medicine, suggest it could potentially provide a cure. In a study of 15 patients — eight with lupus, four with systemic sclerosis (scleroderma), and three with idiopathic inflammatory myositis, a rare muscle disease — researchers eliminated or reduced symptoms and disease biomarkers with a single infusion of CAR-T cells designed to target B cells, immune cells that play a key role in driving autoimmunity. There were no relapses among lupus patients, who were monitored for up to two years after treatment. The myositis and sclerosis patients, who had shorter-term follow-up (usually about three to six months but up to a year) saw their symptoms significantly lessen. https://lnkd.in/gw2xRpQV #cartcelltherapy #cartcells #cartcellmanufacturing

CAR-T Cell Therapy is an interesting treatment approach that is being studied for different cancers, as part of various clinical trials. I came across this paper, which took case studies of engineered CD19 CAR-T Cells to treat patients with 3 different autoimmune diseases, and observed the efficacy of this therapy. Sharing the link for the paper here: https://lnkd.in/dVfuARmf

A new study published in #NatureMedicine is a comprehensive meta-analysis led by investigators at #MemorialSloanKettering Cancer Center (MSK) found that infections are the main cause of Non relapse mortality (NRM) following CAR T cell therapy. This study analyzed outcomes for 7,604 patients across 18 clinical trials and 28 real-world studies, making it the largest on this topic to date. Major causes of mortality post cell therapy ⚡ Infections: Infections caused just over one-half of Non relapse deaths (50.9%). ⚡ Secondary Malignancies: Secondary malignancies accounted for 7.8% of Non relapse deaths. ⚡ Cardiovascular/Respiratory Events: Cardiovascular or respiratory events were responsible for 7.3% of Non relapse deaths. ⚡ CAR T Cell-Specific Toxicities: These included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hemophagocytic lymphohistiocytosis (HLH). Collectively, they contributed to only 11.5% of nonrelapse deaths. Study also highlights that NRM varies by indications and being highest in patients with mantle cell lymphoma (10.6%), followed by multiple myeloma (8.0%), large B cell lymphoma (6.1%), and indolent lymphoma (5.7%). Its an important study and one that can help determine treatment choice as non-relapse mortality rates vary by CAR T cell therapy product. #Celltherapy #CART #realworlddata #CARTtoxicities #lymphoma #secondarymalignancy #Infections https://lnkd.in/gx8r26nN

CAR-T cells are primarily known for their role in treating specific cancers, they have also shown promise in addressing autoimmune conditions like lupus. Recently, Peng and his research team developed a modified version of CAR-T cells. These cells were engineered to target eosinophils, which play a key role in type 2 asthma. In a mouse model, a single dose of these modified CAR-T cells effectively prevented asthma symptoms for up to a year—a significant breakthrough in asthma research. Reference: 1) https://lnkd.in/gxCVSvZ3 2) https://lnkd.in/gCvaVswu

Interesting what is the not yet fully known potential of application of CD89-IgA antibodies. See more on Alzheimer Disease (AD) here: